Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 1/2009

01.02.2009 | BH4 and PKU

Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU

verfasst von: F. J. van Spronsen, M. van Rijn, B. Dorgelo, M. Hoeksma, A. M. Bosch, M. F. Mulder, J. B. C. de Klerk, T. de Koning, M. Estela Rubio-Gozalbo, M. de Vries, P. H. Verkerk

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Summary

Background:

The clinical severity of phenylalanine hydroxylase deficiency is usually defined by either pre-treatment phenylalanine (Phe) concentration or Phe tolerance at 5 years of age. So far, little is known about the course of Phe tolerance or the ability of both pre-treatment Phe and Phe tolerance at early age to predict Phe tolerance at later age.

Aim:

This study was conducted to investigate the course of the individual Phe tolerance and to assess the predictive value of both the pre-treatment Phe concentration and Phe tolerance at 1 and 6 months and 1, 2, 3 and 5 years for Phe tolerance at 10 years of age.

Method:

Data on blood Phe concentration, prescribed Phe intake and weight of 213 early and continuously treated Dutch PKU patients up to 10 years of age were collected. Data acquired under good metabolic control were used in the study. Tolerance was expressed in mg/day and mg/kg per day.

Results:

Data at 1 and 6 months and at 1, 2, 3 and 5 years of 61, 58, 59, 57, 56 and 59 patients were included for comparison with the Phe tolerance at 10 years. Phe tolerances (mg/kg per day) at 2, 3 and 5 years showed a clear correlation with the tolerance at 10 years of age (r = 0.608, r = 0.725 and r = 0.661). Results for tolerance expressed as mg/day were comparable. Pre-treatment Phe concentrations did not correlate significantly with the tolerance.

Conclusion:

Pre-treatment Phe is unreliable but Phe tolerance is a reliable predictor of the tolerance at 10 years of age, starting at 2 years of age.
Literatur
Zurück zum Zitat Burgard P, Rupp A, Konecki DS, Trefz FK, Schmidt H, Lichter-Konecki U (1996) Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. Eur J Pediatr 155(Supplement 1): S11–S15. doi:10.1007/PL00014222.PubMedCrossRef Burgard P, Rupp A, Konecki DS, Trefz FK, Schmidt H, Lichter-Konecki U (1996) Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. Eur J Pediatr 155(Supplement 1): S11–S15. doi:10.​1007/​PL00014222.PubMedCrossRef
Zurück zum Zitat Burton BK, Grange DK, Milanowski A, et al (2007) The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 30: 700–707. doi:10.1007/s10545-007-0605-z.PubMedCrossRef Burton BK, Grange DK, Milanowski A, et al (2007) The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 30: 700–707. doi:10.​1007/​s10545-007-0605-z.PubMedCrossRef
Zurück zum Zitat Goris AH, Westerterp KR (2000) Improved reporting of habitual food intake after confrontation with earlier results on food reporting. Br J Nutr 83: 363–369.PubMed Goris AH, Westerterp KR (2000) Improved reporting of habitual food intake after confrontation with earlier results on food reporting. Br J Nutr 83: 363–369.PubMed
Zurück zum Zitat Guldberg P, Rey F, Zschocke J, et al (1998) A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63: 71–79. doi:10.1086/301920.PubMedCrossRef Guldberg P, Rey F, Zschocke J, et al (1998) A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63: 71–79. doi:10.​1086/​301920.PubMedCrossRef
Zurück zum Zitat Güttler F (1980) Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. Acta Paediatr Scand Suppl 280: 1–80.PubMed Güttler F (1980) Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. Acta Paediatr Scand Suppl 280: 1–80.PubMed
Zurück zum Zitat Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR (1997) Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype–phenotype correlations. Am J Hum Genet 61: 1309–1317. doi:10.1086/301638.PubMedCrossRef Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR (1997) Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype–phenotype correlations. Am J Hum Genet 61: 1309–1317. doi:10.​1086/​301638.PubMedCrossRef
Zurück zum Zitat Levy HL, Milanowski A, Chakrapani A, et al (2007) Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 370: 504–510. doi:10.1016/S0140-6736(07)61234-3.PubMedCrossRef Levy HL, Milanowski A, Chakrapani A, et al (2007) Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 370: 504–510. doi:10.​1016/​S0140-6736(07)61234-3.PubMedCrossRef
Zurück zum Zitat Lichter-Konecki U, Rupp A, Konecki DS, Trefz FK, Schmidt H, Burgard P (1994) Relation between phenylalanine hydroxylase genotypes and phenotypic parameters of diagnosis and treatment of hyperphenylalaninaemic disorders. German Collaborative Study of PKU. J Inherit Metab Dis 17: 362–365. doi:10.1007/BF00711831.PubMedCrossRef Lichter-Konecki U, Rupp A, Konecki DS, Trefz FK, Schmidt H, Burgard P (1994) Relation between phenylalanine hydroxylase genotypes and phenotypic parameters of diagnosis and treatment of hyperphenylalaninaemic disorders. German Collaborative Study of PKU. J Inherit Metab Dis 17: 362–365. doi:10.​1007/​BF00711831.PubMedCrossRef
Zurück zum Zitat MacDonald A, Rylance G, Hall SK, Asplin D, Booth IW (1996) Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch Dis Child 74: 412–417.PubMedCrossRef MacDonald A, Rylance G, Hall SK, Asplin D, Booth IW (1996) Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch Dis Child 74: 412–417.PubMedCrossRef
Zurück zum Zitat Medical Research Council (1993) Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. Arch Dis Child 68: 426–427.CrossRef Medical Research Council (1993) Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. Arch Dis Child 68: 426–427.CrossRef
Zurück zum Zitat Trefz FK, Batzler U, Konig T, et al (1990) Significance of the in vivo deuterated phenylalanine load for long-term phenylalanine tolerance and psycho-intellectual outcome in patients with PKU. Eur J Pediatr 149(Supplement 1): S25–S27. doi:10.1007/BF02126295.PubMedCrossRef Trefz FK, Batzler U, Konig T, et al (1990) Significance of the in vivo deuterated phenylalanine load for long-term phenylalanine tolerance and psycho-intellectual outcome in patients with PKU. Eur J Pediatr 149(Supplement 1): S25–S27. doi:10.​1007/​BF02126295.PubMedCrossRef
Zurück zum Zitat Verkerk PH, Vaandrager GJ, Sengers RC (1990) 15 years of national screening for phenylketonuria in The Netherlands; 4th Report of the National Commission for Management of Phenylketonuria. Ned Tijdschr Geneeskd 134: 2533–2536.PubMed Verkerk PH, Vaandrager GJ, Sengers RC (1990) 15 years of national screening for phenylketonuria in The Netherlands; 4th Report of the National Commission for Management of Phenylketonuria. Ned Tijdschr Geneeskd 134: 2533–2536.PubMed
Zurück zum Zitat Walter JH, White FJ (2004) Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 16: 41–45.PubMed Walter JH, White FJ (2004) Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 16: 41–45.PubMed
Metadaten
Titel
Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU
verfasst von
F. J. van Spronsen
M. van Rijn
B. Dorgelo
M. Hoeksma
A. M. Bosch
M. F. Mulder
J. B. C. de Klerk
T. de Koning
M. Estela Rubio-Gozalbo
M. de Vries
P. H. Verkerk
Publikationsdatum
01.02.2009
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 1/2009
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-008-0937-3

Weitere Artikel der Ausgabe 1/2009

Journal of Inherited Metabolic Disease 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.